Leif Bertilsson

Karolinska University Hospital — Sweden

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

85h-index22.7kcitations341works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(147), Pharmacological Effects and Toxicity Studies(53), Epilepsy research and treatment(43), Neurotransmitter Receptor Influence on Behavior(40), Drug Transport and Resistance Mechanisms(37)

Publications341 total

Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug–Drug Interaction in Healthy Volunteers
Journal of Personalized Medicine·2021· 9 citedOpen Access
Tribute to Folke Sjöqvist, a Pioneer in Clinical Pharmacology
Clinical Pharmacology & Therapeutics·2020
Develoment of pharmacogenomicsduring 40 years―CYP2D6 and CYP2C19 as examples
2019
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
Scientific Reports·2018· 10 citedOpen Access
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
European Journal of Clinical Pharmacology·2018· 12 citedOpen Access
Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients
BMC Pharmacology and Toxicology·2018· 16 citedOpen Access
N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians
European Journal of Clinical Pharmacology·2018· 27 citedOpen Access
Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients
Antimicrobial Agents and Chemotherapy·2017· 13 citedOpen Access
Decreased Activity and Genetic Polymorphisms of<scp>CYP</scp>2C19 in Behçet's Disease
Basic & Clinical Pharmacology & Toxicology·2016· 8 citedOpen Access
Prevalence and risk factors for efavirenz-based antiretroviral treatment–associated severe vitamin D deficiency
Medicine·2016· 21 citedOpen Access
MP666INFLAMMATION DOWN REGULATES CYTOCHROME P450 MEDINATED DRUG METABOLISM IN HEMODIALYSIS PATIENTS
Nephrology Dialysis Transplantation·2016· 1 citedOpen Access
Long‐Term Effect of Rifampicin‐Based Anti‐TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8‐Hydroxy‐Efavirenz in Ethiopian Patients
The Journal of Clinical Pharmacology·2016· 18 cited
Comparison of genotype and variant allele frequency distribution between Ethiopian and Tanzanian HIV patients.
Figshare·2015Open Access
The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans
Journal of Clinical Psychopharmacology·2015· 28 cited
Lower CYP2C9 activity in Turkish patients with Behçet’s disease compared to healthy subjects: a down-regulation due to inflammation?
European Journal of Clinical Pharmacology·2015· 16 citedOpen Access
Differences in <i>CYP2C9</i> Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex
OMICS A Journal of Integrative Biology·2015· 23 cited
Is There a Need to Increase the Dose of Efavirenz During Concomitant Rifampicin-Based Antituberculosis Therapy in Sub-Saharan Africa? The HIV-TB Pharmagene Study
Pharmacogenomics·2015· 22 cited
Genetic and Clinical Factors Affecting Plasma Clozapine Concentration
The Primary Care Companion For CNS Disorders·2015· 33 cited
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4 -hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
Journal of Antimicrobial Chemotherapy·2014· 26 citedOpen Access
Plasma Levels of 25‐Hydroxyvitamin <scp>D</scp><sub>3</sub> and <i>In Vivo</i> Markers of Cytochrome <scp>P</scp>450 3<scp>A</scp> Activity in Swedes and Koreans: Effects of a Genetic Polymorphism and Oral Contraceptives
Basic & Clinical Pharmacology & Toxicology·2014· 9 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

Magnus Ingelman‐Sundberg(10), Marja­‐Liisa Dahl(10), Folke Sjöqvist(7), Eleni Aklillu(6), Marie Åsberg(6), Inger Johansson(5), Gunnel Tybring(5), Juliette Säwe(4), Ulf Diczfalusy(4), Peter Thorén(3), M-L Dahl(3), Adrián LLerena(3), Anna Åberg‐Wistedt(3), Conny Nordin(3), Michel Eichelbaum(3), Christina Alm(3), Lil Träskman(2), Vivi‐Ann Ringberger(2), Per Dalén(2), C. Alm(2)